Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway.

"the data discussed in this study have been deposited in the ncbi's gene expression omnibus and are accessible through geo series accession number gse203044.; the datasets generated and analysed during the current study are available in the ncbi's gene expression omnibus repository accession number gse203044."

"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number [JP22K09557 to YI and JP20K09610 to NY]."